# Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

> **NCT01751308** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 39 (actual)

## Conditions studied

- Malignant Solid Tumor - Malignant Nervous System Neoplasm

## Interventions

- **DRUG:** Cabazitaxel (XRP6258)

## Key facts

- **NCT ID:** NCT01751308
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2015-07
- **Final completion:** 2016-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751308, "Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01751308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*